General Information of Drug Therapeutic Target (DTT) (ID: TTMO9HF)

DTT Name Advanced glycosylation end product receptor (AGER)
Synonyms Receptor foradvanced glycosylation end products; RAGESEC; RAGE; AGER
Gene Name AGER
DTT Type
Clinical trial target
[1]
BioChemical Class
Immunoglobulin
UniProt ID
RAGE_HUMAN
TTD ID
T07400
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MAAGTAVGAWVLVLSLWGAVVGAQNITARIGEPLVLKCKGAPKKPPQRLEWKLNTGRTEA
WKVLSPQGGGPWDSVARVLPNGSLFLPAVGIQDEGIFRCQAMNRNGKETKSNYRVRVYQI
PGKPEIVDSASELTAGVPNKVGTCVSEGSYPAGTLSWHLDGKPLVPNEKGVSVKEQTRRH
PETGLFTLQSELMVTPARGGDPRPTFSCSFSPGLPRHRALRTAPIQPRVWEPVPLEEVQL
VVEPEGGAVAPGGTVTLTCEVPAQPSPQIHWMKDGVPLPLPPSPVLILPEIGPQDQGTYS
CVATHSSHGPQESRAVSISIIEPGEEGPTAGSVGGSGLGTLALALGILGGLGTAALLIGV
ILWQRRQRRGEERKAPENQEEEEERAELNQSEEPEAGESSTGGP
Function
Mediates interactions of advanced glycosylation end products (age). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Receptor for amyloid beta peptide.
KEGG Pathway
Neutrophil extracellular trap formation (hsa04613 )
AGE-RAGE signaling pathway in diabetic complications (hsa04933 )
Alzheimer disease (hsa05010 )
Pathways of neurodegeneration - multiple diseases (hsa05022 )
Diabetic cardiomyopathy (hsa05415 )
Lipid and atherosclerosis (hsa05417 )
Reactome Pathway
DEx/H-box helicases activate type I IFN and inflammatory cytokines production (R-HSA-3134963 )
TAK1 activates NFkB by phosphorylation and activation of IKKs complex (R-HSA-445989 )
Advanced glycosylation endproduct receptor signaling (R-HSA-879415 )
TRAF6 mediated NF-kB activation (R-HSA-933542 )
RIP-mediated NFkB activation via ZBP1 (R-HSA-1810476 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
5 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
PF-4494700 DMJ7IKW Alzheimer disease 8A20 Phase 3 [1]
Pyridoxamine DMVDCGZ Diabetic kidney disease GB61.Z Phase 3 [2]
Alagebrium chloride DMD741P Hypotension BA20-BA21 Phase 2/3 [3]
TTP-448 DMR37X8 Alzheimer disease 8A20 Phase 2 [1]
TTP-4000 DMCG01R Alzheimer disease 8A20 Phase 1 [4]
------------------------------------------------------------------------------------
1 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
DBT-066 DMFYCQ1 Dementia 6D80-6D86 Investigative [5]
------------------------------------------------------------------------------------

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Alzheimer's disease 8A00.0 Entorhinal cortex 7.92E-01 6.77E-03 0.04
------------------------------------------------------------------------------------

References

1 Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease. Expert Opin Investig Drugs. 2015 Mar;24(3):393-9.
2 Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice. Protein Pept Lett. 2010 Sep;17(9):1177-81.
3 Effect of the age cross-link breaker alagebrium on anterior segment physiology, morphology, and ocular age and rage. Trans Am Ophthalmol Soc. 2009 Dec;107:146-58.
4 Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases. Future Neurol. 2009; 4(2): 167-177.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2843).